ABSTRACT
BACKGROUND: Invasive Aspergillus sinusitis (IAS) is associated with high mortality and poor response to antifungal therapy in patients with hematologic malignancies (HM). PATIENTS AND METHODS: We identified 353 patients with invasive aspergillosis of whom 39 patients had IAS. Of the 39 patients, 13 underwent sinus surgery (SS) in addition to the antifungal therapy, and the remaining 26 control patients received antifungal therapy alone. Most patients with IAS had underlying leukemia (85%). Both groups had comparable clinical characteristics such as gender, age, underlying disease, neutropenia at the onset, persistent neutropenia, graft-vs-host-disease, and comparable antifungal therapy. RESULTS: Overall response was 7 (53.2%) in the SS group vs 5 (19.2%) in the control group (p = 0.06). Among the subgroup of patients with neutropenia at the onset of infection, the response rate in the SS group was significantly better than in the non-SS group (57% vs 11.8%, respectively; p = 0.028). CONCLUSION: In neutropenic patients with IAS and underlying HM, SS significantly improved the response to antifungal therapy. Additional studies are warranted.
Subject(s)
Antifungal Agents/therapeutic use , Aspergillosis , Aspergillus flavus/isolation & purification , Hematologic Neoplasms/complications , Neutropenia/complications , Sinusitis , Adult , Aspergillosis/drug therapy , Aspergillosis/microbiology , Aspergillosis/surgery , Aspergillus flavus/classification , Female , Humans , Male , Middle Aged , Sinusitis/drug therapy , Sinusitis/microbiology , Sinusitis/surgery , Treatment OutcomeABSTRACT
In patients with hematologic malignancy, invasive aspergillosis continues to be associated with high mortality even when treated with conventional antifungal therapy. To investigate novel antifungal agents, we compared 53 patients who received posaconazole salvage therapy to 52 contemporary control patients who received high-dose lipid formulation of amphotericin B (HD-LPD/AMB at > or = 7.5 mg kg(-1) per day) and 38 other control patients who received caspofungin plus HD-LPD/AMB. Patients in the three groups had similar. The overall response rate to salvage therapy was 40% for posaconazole, 8% for HD-LPD/AMB (P < or = 0.001) and 11% for combination therapy (P < 0.002). Aspergillosis contributed to the death of 40% of posaconazole group, 65% of the HD-LPD/AMB group and 68% of the combination group (P < or = 0.008). By multivariate analysis, posaconazole therapy independently improved response (9.5; 95% confidence interval, 2.8-32.5; P < 0.001). HD-LPD/AMB alone or in combination was associated with a significantly higher rate of nephrotoxicity (P < or = 0.02) and hepatotoxicity (P < 0.03). In conclusion, posaconazole salvage therapy demonstrated greater efficacy and safety than HD-LPD/AMB alone or in combination with caspofungin in the salvage therapy of invasive aspergillosis in hematologic malignancy.
Subject(s)
Antifungal Agents/therapeutic use , Aspergillosis/drug therapy , Fungemia/drug therapy , Hematologic Neoplasms/complications , Salvage Therapy , Triazoles/therapeutic use , Adult , Amphotericin B/administration & dosage , Amphotericin B/therapeutic use , Antifungal Agents/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Aspergillosis/etiology , Caspofungin , Combined Modality Therapy , Drug Combinations , Drug Therapy, Combination , Echinocandins/administration & dosage , Echinocandins/therapeutic use , Female , Hematologic Neoplasms/drug therapy , Hematologic Neoplasms/surgery , Hematopoietic Stem Cell Transplantation , Humans , Itraconazole/administration & dosage , Itraconazole/therapeutic use , Lipopeptides , Male , Middle Aged , Neutropenia/chemically induced , Neutropenia/complications , Phosphatidylcholines/administration & dosage , Phosphatidylcholines/therapeutic use , Phosphatidylglycerols/administration & dosage , Phosphatidylglycerols/therapeutic use , Pyrimidines/administration & dosage , Pyrimidines/therapeutic use , Treatment Outcome , Triazoles/administration & dosage , VoriconazoleABSTRACT
Factors associated with failure of antifungal therapy were examined in 42 cancer patients with fusariosis (1987-1997). Thirty-six patients (86%) had leukemia and 39 (93%) were neutropenic. Disseminated infection was the most common presentation. The majority (83%) received amphotericin B-based therapy. Thirty patients (71%) failed therapy. No patient with persistent neutropenia responded.
Subject(s)
Fusarium , Hematologic Neoplasms/complications , Mycoses/complications , Mycoses/diagnosis , Neutrophils/physiology , Adolescent , Adult , Aged , Aged, 80 and over , Female , Hematologic Neoplasms/microbiology , Humans , Leukocyte Count , Male , Middle Aged , Mycoses/drug therapy , Mycoses/immunology , Neutropenia/complications , Neutropenia/microbiology , Neutrophils/cytology , Treatment OutcomeABSTRACT
The risk factors for and presentation of Candida tropicalis fungemia, in comparison with those of Candida albicans, have been incompletely characterized. We compared 43 cases of C. tropicalis fungemia with 148 cases of C. albicans fungemia. In univariate analysis, patients with C. tropicalis fungemia were more likely to have leukemia (P=.0006), prolonged neutropenia (P=.03), and a positive blood culture for more days (P=.02). The 2 groups did not differ with regard to baseline Acute Physiology and Chronic Health Evaluation (APACHE) II score, frequency of catheter-associated fungemia, or response to antifungals. In multivariate analysis, patients with C. tropicalis fungemia were more likely to have leukemia (P=.02), previous neutropenia (P=.002), and a longer stay in the intensive care unit during the infectious episode (P=.01). Also, the response of the breakthrough C. tropicalis fungemia was lower (P=.05). In conclusion, the host determinants associated with susceptibility to C. tropicalis are leukemia and prolonged neutropenia.
